Mission Cure Capital
Mission Cure Capital (MCC) is the first and only mission-driven impact investment company focused on Pancreatitis. MCH invests in commercially-promising research and development projects that will improve the lives of children and adults suffering from pancreatitis. Pancreatitis is a genetically-driven, debilitating disease that causes inflammation and severe pain and leads to digestive dysfunction, diabetes and an increased risk of pancreatic cancer. Chronic and recurrent acute pancreatitis affects over 600,000 people in the United States alone plus millions more worldwide. There are currently no effective treatments or cures but with clear priorities and our focused investment strategy, we intend to change that.
Mission Cure Capital is a mission-driven venture capital firm specializing in life sciences and biotechnology, specifically focusing on R&D for pancreatitis treatments, precision medicine, and drug development.
Naples, Florida, United States
Venture Capital and Private Equity Principals
venture capital
healthcare, biotechnology, life sciences, pharmaceuticals
biotech investing, pancreatic disease, pancreatitis, impact investing, chronic pancreatitis, recurrent acute pancreatitis, pediatric pancreatitis, hereditary pancreatitis, medical research funding
—
—
1
2019
healthcare · biotechnology, life sciences, pancreatitis therapies, drug development, genomic health IT, precision medicine, regenerative medicine
Done
Prospects
No prospects linked to this account.
Outreach History
Outreach sequencing tables are not yet in Supabase.